POS-320 INSIDE ANEMIA OF CKD: QUANTIFYING THE EPIDEMIOLOGICAL BURDEN OF ANEMIA OF CKD IN CANADA VIA MICROSIMULATION MODELLING

• J.J. GARCIA SANCHEZ,
• L. Retat,
• L. Webber,
• C. Cabrera,
• S. Grandy,
• N. Rao,
• P. Bhatt,
• A. Parackal,
• D. Wong,
• J. Wish,
• N. Tangri

Affiliations

J.J. GARCIA SANCHEZ

AstraZeneca, Health Economics, Cambridge, United Kingdom

L. Retat

HealthLumen, Senior Health Economist & Mathematical Modeller, London, United Kingdom

L. Webber

HealthLumen, Co-founder and COO, London, United Kingdom

C. Cabrera

AstraZeneca, Epidemiology & Evidence Excellence, Gothenburg, Sweden

S. Grandy

AstraZeneca, Global Pricing and Market Access, Gaithersburg, United States

N. Rao

AstraZeneca, Global Pricing and Market Access, Cambridge, United Kingdom

P. Bhatt

AstraZeneca, Biopharmaceuticals Medical, Wilmington, United States

A. Parackal

AstraZeneca, Innovation- Value & Access Strategy, Mississauga, Canada

D. Wong

AstraZeneca, Innovation- Value & Access Strategy, Mississauga, Canada

J. Wish

Indiana University School of Medicine, Division of Nephrology, Indianapolis, United States

N. Tangri

University of Manitoba, Chronic Disease Innovation Center, Winnipeg, Canada